Inferra AIResearch Tools

Inferra AI / Company / MRNA

Moderna

MRNA · Health Care

Last earnings Jul 31, 2026  ·  Next earnings Nov 6, 2026

Key results

Total revenuequarter

$142 million

1 Second Quarter 2025 Financial Results Revenue Total revenue for the second quarter of 2025 was $142 million, a 41% decrease from $241 million in the same period in 2024.

SEC original ↗Moderna — Earnings release (8-K exhibit)EX-99Aug 1, 2025

AI analysis

Q2 2025 · reported Aug 1, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Total revenue · Q2 2025
$142M
EX-99 · Aug 1, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Total revenue$142 million——

EX-99 · Aug 1, 2025

Guidance · company-stated

No guidance located in the held release

Stated figure10%

“97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.”

Next earningsNov 6, 2026Verified from the company’s own announcement

Capital allocation

Capex$0.3B

Capital Expenditures Capital expenditures for 2025 are expected to be approximately $0.3 billion, lowered from previous expectations of approximately $0.4 billion.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine CAMBRIDGE, MA ACCESSWIRE August 1, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Capital Expenditures Capital expenditures for 2025 are expected to be approximately $0.3 billion, lowered from previous expectations of approximately $0.4 billion.

SEC original ↗Moderna — Earnings release (8-K exhibit)EX-99Aug 1, 2025

Additionally, for the three and six months ended June 30, 2026, the net cost recovery for capital expenditures was $ 1 million and $ 2 million , respectively.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

treasury notes 2,132 ( 9 ) 2,123 1,399 724 Corporate debt securities 2,371 1 ( 6 ) 2,366 1,371 995 Government debt securities 55 55 2 53 Total $ 6,925 $ 1 $ ( 16 ) $ 6,910 $ 1,723 $ 3,415 $ 1,772 December 31, 2025 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Current Marketable Securities Non- Current Marketable Securities Cash and cash equivalents $ 2,595 $ $ $ 2,595 $ 2,595 $ $ Available-for-sale: Certificates of deposit 91 91 86 5 U.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

treasury notes ( 6 ) 1,519 ( 3 ) 236 ( 9 ) 1,755 Corporate debt securities ( 6 ) 1,510 28 ( 6 ) 1,538 Government debt securities 55 55 Total $ ( 13 ) $ 3,753 $ ( 3 ) $ 264 $ ( 16 ) $ 4,017 As of December 31, 2025: U.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

treasury notes ( 1 ) 176 ( 2 ) 235 ( 3 ) 411 Corporate debt securities 608 ( 1 ) 40 ( 1 ) 648 Government debt securities 36 8 44 Total $ ( 1 ) $ 931 $ ( 3 ) $ 283 $ ( 4 ) $ 1,214 As of June 30, 2026 and December 31, 2025, we held 283 and 108 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

treasury notes 2,123 2,123 Corporate debt securities 2,440 2,440 Government debt securities 55 55 Equity investments (1) 2 2 Derivative instruments 2 2 Total $ 6,838 $ 1,449 $ 5,389 Fair value at December 31, 2025 Fair Value Measurement Using Level 1 Level 2 Assets: Money market funds $ 963 $ 963 $ Certificates of deposit 91 91 U.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

Strategy & priorities

The obligations under the Credit Agreement are guaranteed by certain of our subsidiaries and are secured by a first-priority lien on substantially all of our assets, in each case subject to customary exceptions and limitations.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

Risks & headwinds

The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

SEC original ↗Moderna — Earnings release (8-K exhibit)EX-99Aug 1, 2025

These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading Risk Factors in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.

SEC original ↗Moderna — Earnings release (8-K exhibit)EX-99Aug 1, 2025

Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our operational or financial performance, and involve risks, uncertainties, and other factors that may cause our actual results to differ materially from any future results expressed or implied by these forward-looking statements.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual results could differ materially from those expressed or implied by the forward-looking statements.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

Legal Proceedings 39 Item 1A.

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

The ASU clarifies that this threshold would not be met when there is significant uncertainty associated with the development activities of the software (referred to as significant development uncertainty ).

SEC original ↗Moderna — 10-Q Quarterly report10-QJul 31, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

62 documents

Earnings releases

26 documents

Presentations

0 documents

No presentations for Moderna are held in this edition of the library.

Transcripts

0 documents

No transcripts for Moderna are held in this edition of the library.

Mentioned by

10 companies

Other tracked companies whose held documents mention Moderna by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.